Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 35Breast Neoplasms 31Prostatic Neoplasms 22Colorectal Neoplasms 21Leukemia, Myeloid, Acute 19Pancreatic Neoplasms 17Melanoma 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Carcinoma, Hepatocellular 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Ovarian Neoplasms 10Myelodysplastic Syndromes 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Locally Recurrent Skin Squamous Cell Carcinoma × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡